AAA today announced that new safety and efficacy data from the pivotal Phase 3 NETTER-1 study investigating the treatment of Lutathera (177-Lu-Dotatate) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (midgut NETs) will be presented on Friday, January 22, 2016 at the 2016 Gastrointestinal Cancer Symposium ASCO GI in San Francisco, California.
The NETTER-1 abstract has also been selected for ASCO GI’s official Press Program and the new findings of the NETTER-1 study will be presented to journalists in a presscast on Tuesday, January 19, 2016 from 12:00-1:30 PM ET.